Suprefact

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Pipeline Insight: Endometriosis - Growing the Patient Population is Key to Unlocking the Markets Commercial Potential to their offering

The current endometriosis market is underdeveloped, due to poor disease awareness and both low presentation and diagnosis rates.

Current therapies are limited in terms of efficacy and often have unwanted side effects.

This report gives an analysis of the endometriosis market, focusing on key R&D products for the disease and investigating existing treatment practices to highlight unmet needs.

Scope of Report:

--Epidemiology of endometriosis in seven major markets, identifying subpopulations and unmet needs

--Detailed profiles of drugs in Phase II and above examining clinical data and benchmarked against gold standard using quantitative SWOT analysis

--Country-specific sales forecasts for the seven major markets, based on IMS MIDAS data covering key ATC classes G3A, G3D, G3H, H1C1 (L2A) and H1C3

--Extensive secondary research and utilization of licensed and in-house databases supplemented by primary research interviews with key opinion leaders

Report Highlights:

The endometriosis market will change dramatically following the patent expiry of key brands Lupron Depot, Zoladex and Suprefact. This presents a challenge for R&D candidates, as pressure on pricing and genericization result in a greater demand for improvements over standard therapies in efficacy, tolerability, side effects and cost-effectiveness.

With an estimated symptomatic population of six million women, there is a significant latent potential. This is due to patients being lost in the treatment pathway through low presentation and diagnosis rates, compounded by poor disease awareness, as well as a lack of an effective, easily accessible, non-invasive diagnostic tool.

Although the pipeline is sparse, the unmet need in the market is such that We forecast combined sales of six late-stage R&D candidates of $2.2 bn by 2014. While GnRH antagonists are natural successors to Lupron and Zoladex, Schering AG/TAPs asoprisnil is expected to drive the pipeline and set the new standard in endometriosis treatment.

Reasons to Purchase:

--Quantify the future size and scope of the market, and the potential for new products

--Benchmark pipeline drugs against currently marketed products with drug profiles and SWOT analysis

--Measure the impact of key patent expiries using the forecasting model

For more information visit http://www.researchandmarkets.com/reports/c5460

COPYRIGHT 2004 Business Wire
COPYRIGHT 2004 Gale Group